ClinicalTrials.gg
CompletedNCT02507284Updated Jul 20, 2023Results posted

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

A Phase 2 interventional study of SRX246 and Placebo in Irritable Mood and Huntington's Disease, sponsored by Azevan Pharmaceuticals. Completed at 22 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Azevan Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.

Enrollment
29th of 90
106 · median 44
Started
2016
with 3 others
Phase 2
28 of 138
none open now
Registered
67th of 138
by date

Among the 138 studies in Huntington Disease with a site in United States, this one is the 29th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2016, is one of 28 in phase 2, and was the 67th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Huntington Disease with a site in United States, or all of them as a file.
02

Study summary

This study evaluates the tolerability, safety and activity of SRX246 in the treatment of irritability in patients with Huntington's disease. Two-thirds of all participants will receive SRX246, while the other third will receive a placebo.

Read the detailed description

SRX246 is a first-in-class vasopressin 1a (V1a) receptor antagonist that crosses the blood-brain barrier following oral administration. The molecule exhibits high affinity and high selectivity for its target receptor. Preclinical pharmacology studies have demonstrated significant CNS effects in models of irritability, including impulsive aggression, depression, and anxiety. In an experimental medicine fMRI study in healthy volunteers, SRX246 treatment significantly attenuated the effect of intranasal AVP in brain circuits known to modulate emotional responses to stimuli that elicit aggression/fear. Together, these findings suggest that SRX246 has potential as a novel therapeutic agent for major neuropsychiatric symptoms seen in HD patients.

This is a 3-arm, multicenter, randomized, placebo-controlled, double-blind, 12 week, dose escalation study of SRX246 in irritable Subjects with early symptomatic HD.

Following an initial screening visit, Subjects fulfilling the study inclusion and exclusion criteria will enter a pre-treatment screening phase to permit evaluations to confirm eligibility for inclusion into the study. This screening phase will be no longer than 30 days. At the completion of the screening period, eligible Subjects will be randomized at baseline visit to receive either placebo or final doses of SRX246 of 120 mg twice daily or 160 mg twice daily during the double-blind treatment phase. At baseline, Subjects in the active groups will receive 80 mg twice daily for 2 weeks, then escalate to 120 mg twice daily for 4 weeks. Then one group of Subjects will continue to take 120 mg of SRX246 twice daily for an additional 6 weeks, and the second group of Subjects will increase their dose to 160 mg of SRX246 twice daily for 6 weeks. Total dosing duration is 12 weeks.

Subjects in the placebo group will receive a similar number of capsules that are identical in appearance to the capsules that contain SRX246 during the trial, in order to preserve the blind.

In all groups, dose escalation will occur (stepwise) if patients have not experienced dose-limiting adverse effects. Patients who cannot tolerate their final dose of drug (or placebo) can have this dose reduced without compromising the blinding.

Subjects will have periodic visits either "in-person" or by "telephone", to assess tolerability, safety, and several measures of irritability and other problem behaviors, and clinical assessments for activity signals.

03

Conditions studied

  • Irritable Mood
  • Huntington's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female Subjects aged 18 years or older
  2. Subjects must have clinical features of HD, which can include motor, cognitive, or behavioral symptoms
  3. A confirmatory family history of HD; OR CAG repeat expansion ≥ 37
  4. Total Functional Capacity (TFC) score of 5-13
  5. Evidence of irritability; a score of at least 2 or greater on the severity measure of either the UHDRS Irritability question (30b) or Aggression question (Disruptive or Aggressive Behavior, 31b)
  6. Women of (i.e., those not or surgically sterile) must have a negative pregnancy test, be non-lactating and use adequate methods during the study. Adequate birth control includes: abstinence; oral, implanted or injected contraceptives, e.g., birth control pills; intra-uterine device; barrier (vaginal ring or diaphragm/cervical cap with spermicide); transdermal patch. Reliable contraception must have been in use 30 days prior to the Baseline Visit. Partner(s) contraception (e.g., male partner with vasectomy or other surgical contraception) is acceptable.
  7. Men must agree not to father a child during the study and one month after and to use contraception. Barrier with spermicide or surgical contraception is acceptable. Partner(s) contraception (e.g., female partner taking birth control pills or surgically sterile) is acceptable.
  8. Subjects must be able to swallow study drug capsules whole.
  9. Sufficient English skills to complete all assessments without assistance of an English language interpreter. Subjects with HD who cannot read or write might qualify for enrollment in the study. Site PIs will have to decide in each case whether the Subject can understand and fully participate with help from his/her Informant.
  10. Availability of a responsible Informant (referred to as a "study partner" in the consent document) who has good English skills, is familiar with the Subject, and is able and willing to comply with all required study procedures, ensuring that the patient attends all study visits and takes the study medicine as instructed. The study partner must spend time with the patient a minimum of 4 times per week on 4 separate days, and must monitor the patient's compliance and adverse events, participate in caregiver assessments, and use the eDiary.
  11. Subject has provided written, or, if Subject lacks the capacity to provide informed consent (as determined by an independent assessment by a qualified healthcare provider not directly involved in other study activities), a legally authorized representative (LAR) has provided written informed consent and the Subject has provided assent.

Exclusion criteria

Exclusion Criteria:

  1. Any significant neurologic disease other than HD at Screening.
  2. Severe psychotic features or other severe psychiatric symptoms within the last three months which could lead to difficulty complying with the protocol.
  3. History of active alcohol or substance abuse within the past two years or Subject is unable to refrain from substance abuse throughout the study.
  4. Any chronic disability, significant systemic illness or unstable medical condition at Screening or Baseline that could lead to difficulty complying with the protocol.
  5. Use of any drugs within 30 days of Screening.
  6. Subject has known allergy to any of the components of study medication.
  7. Subject is currently pregnant, breast-feeding and/or lactating.
  8. Subject acknowledges present use of illicit drugs at Screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    SRX246 120mg BID

    SRX246 capsules, administered orally, in divided doses twice daily

    Drug: SRX246

  • Experimental
    SRX246 160mg BID

    SRX246 capsules, administered orally, in divided doses twice daily

    Drug: SRX246

  • Placebo comparator
    Placebo

    Placebo capsules, administered orally, in divided doses twice daily

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Tolerability of SRX246

    The primary endpoint, tolerability of SRX246, was assessed by the number of completers in each group.

    Time frame: 12 weeks

Secondary outcomes

  1. Safety of SRX246

    The Safety of SRX246 was assessed by the number of participants who experience an adverse event.

    Time frame: 12 weeks

07

Results

Posted Jul 20, 2023

Participant flow

Participant flow — Overall Study
MilestoneSRX246 120mg BIDSRX246 160mg BIDPlacebo
Started363436
Completed252730
Not completed1176

Outcome measures

PrimaryTolerability of SRX246

The primary endpoint, tolerability of SRX246, was assessed by the number of completers in each group.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Tolerability of SRX246
ParticipantsSRX246 120mg BIDSRX246 160mg BIDPlacebo
Tolerability of SRX246252730
SecondarySafety of SRX246

The Safety of SRX246 was assessed by the number of participants who experience an adverse event.

Time frame:
12 weeks
Reported as:
Count of participants · Participants
Safety of SRX246
ParticipantsSRX246 120mg BIDSRX246 160mg BIDPlacebo
Safety of SRX246293026
Statistical analysis
  • SRX246 120mg BID vs SRX246 160mg BID vs Placebo · t-test, 1 sided · p = 0.50 · Risk ratio (rr): 0.025

Adverse events

Collected over From first dose of study drug to last date of patient follow-up at end of study (an average of 12-weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SRX246 120mg BID0/36 (0%)5/36 (13.9%)29/36 (80.6%)
SRX246 160mg BID0/34 (0%)0/34 (0%)30/34 (88.2%)
Placebo0/36 (0%)0/36 (0%)26/36 (72.2%)
Most frequent serious events
Most frequent serious events
EventSRX246 120mg BIDSRX246 160mg BIDPlacebo
Aggression and IrritabilityPsychiatric disorders2/360/340/36
Angina pectorisCardiac disorders1/360/340/36
Ankle fractureMusculoskeletal and connective tissue disorders1/360/340/36
Renal neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/360/340/36
Most frequent other events
Most frequent other events
EventSRX246 120mg BIDSRX246 160mg BIDPlacebo
nauseaGastrointestinal disorders7/369/344/36
Upper Respiratory Tract InfectionInfections and infestations6/364/349/36
depressed moodPsychiatric disorders8/368/344/36
headacheNervous system disorders6/364/348/36
FatigueGeneral disorders3/365/342/36
ArthralgiaMusculoskeletal and connective tissue disorders5/365/341/36
FallInjury, poisoning and procedural complications4/364/345/36

Baseline characteristics

Age, Continuous
Age, Continuous(years)SRX246 120mg BIDSRX246 160mg BIDPlaceboTotal
Mean51.1 ± 13.248.9 ± 12.751.7 ± 10.450.6 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)SRX246 120mg BIDSRX246 160mg BIDPlaceboTotal
Female18172055
Male18171651
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SRX246 120mg BIDSRX246 160mg BIDPlaceboTotal
White363336105
Not White0101
Hispanic/Latino2406
Not Hispanic/Latino34303599
Missing0011
Region of Enrollment
Region of Enrollment(participants)SRX246 120mg BIDSRX246 160mg BIDPlaceboTotal
United States363436106
08

Study locations

22 sites
  • University of Alabama
    Birmingham, Alabama 35233, United States
  • UCLA, Neurology Clinic
    Los Angeles, California 90095, United States
  • UC Davis Medical Center, Department of Neurology, CTSC Clinical Research Center
    Sacramento, California 95817, United States
  • University of Colorado Hospital Translational Research Center
    Aurora, Colorado 80045, United States
  • University of Miami, Miller School of Medicine, Jackson Behavioral Health Hospital
    Miami, Florida 33136, United States
  • Emory University
    Atlanta, Georgia 30329, United States
  • Northwestern Out-Patient Neurology Clinic
    Chicago, Illinois 60611, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Charlestown, Massachusetts 02129, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • SUNY Stony Brook Clinical Research Center, Department of Neurology
    East Setauket, New York 11733, United States
  • Columbia University Medical Center, New York Presbyterian Hospital
    New York, New York 10032, United States
  • University of Rochester Medical Center
    Rochester, New York 14618, United States
  • University Medical Arts Building
    Cincinnati, Ohio 45219, United States
  • Ohio State University, Wexner Medical Center, Department of Neurology
    Columbus, Ohio 43221, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • University of Pittsburgh Medical Center, Department of Neurology
    Pittsburgh, Pennsylvania 15213, United States
  • Vanderbilt Clinical Research Center
    Nashville, Tennessee 37232, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Utah, Department of Neurology
    Salt Lake City, Utah 84108, United States
  • University of Virginia Health System, Department of Neurology
    Charlottesville, Virginia 22908, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Sep 2018, 28 months.

Results were first posted in Jul 2023, 4 years 10 months after primary completion.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 28 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2015
First posted
Jul 23, 2015
StartActual
May 10, 2016
Primary completionActual
Sep 10, 2018
CompletionActual
Dec 21, 2018
Results first posted
Jul 20, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02507284
Lead sponsor
Azevan Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 23, 2015
Start date
May 10, 2016
Primary completion
Sep 10, 2018
Completion
Dec 21, 2018
Results posted
Jul 20, 2023
Last update
Jul 20, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SRX246

Start the discussion